## . Methotrexate entrained in the hyaluronan meshwork





FIGURE 1

Substitute Sheet (Rule 26)(RO/AU)


A: Possible Interactions netween Methotresage and Byaynonan (") and the line of the line o

B: Entanglement, of Methotrexate in Uvaluconan Melecule



.FIGURE . 2

ii: Uydrogen Bonding







FIGURE 3
SUBSTITUTE SHEET (RULE 26) (RO/AU)

4/28








FIGURE 4
SUBSTITUTE SHEET (RULE 26) (RO/AU)




FIGURE"5

SUBSTITUTE SHEET (RULE 26) (RO/AU)

Molecular weight characterisation of hyaluronan used as a delivery vehicle for methotrexate



FACURE . A



FTGURE T SUBSTITUTE SHEET (RULE 26) (RO/AU)

# Increased methotrexate uptake by the liver when drug is co-administered with hyaluronan





FIGURE 8



Time after injection (hours)

FIGURE 9

#### 10/28




FIGURE 10.

drug internalisation mechanisms





FIGURE 11

SUBSTITUTE SHEET (RULE 26) (RO/AU)

# Tumour Uptake of 5-Fluorouracil




Time After injection (min)

\* P= or< 0.001, Students t-test

FIGURE 12

14 gr



#### FIGURE 13

<sup>\*</sup> Local catabolism will almost certainly dominate in very dense tissues, or these without lymphatic drainage, for example, bone and cartilage

FIGURE 14
SUBSTITUTE SHEET (RULE 26) (RO/AU)

ogeogae, czae







FIGURE 15

### 16/28






FIGURE 16




FIGURE 17









FIGURE 18







**Treatment Groups** 

FIGURE 19
SUBSTITUTE SHEET (RULE 26) (RO/AU)










FIGURE 20
SUBSTITUTE SHEET (RULE 26) (RO/AU)

, 1

COMMOND. CINEROL

# 6 Month Study: Survival Curves




FIGURE 21

Effect of CMF/HA therapy on body mass: 6-week study




FIGURE 22

ogesea.carde

1. 18 18 18 CAR

Effect of CMF/HA adjuvant therapy on primary tumour mass




FIGURE 23

ppm

1

2

10/11

6

10/11

FIGURE 24

### FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28